Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2011	Dec. 31, 2010
Successor
Current assets:
Cash and cash equivalents	$ 14,840,392	$ 867,738
Accounts receivable, net	234,418	229,891
Inventory, net	315,931	258,939
Prepaid expenses and other current assets	1,372,043	559,082
Total current assets	16,762,784	1,915,650
Property and equipment, net of accumulated depreciation of $83,787 and $8,085, respectively	732,328	21,589
Intangible assets and other	6,340,906	6,340,906
Total assets	23,836,018	8,278,145
Current liabilities:
Current debt	6,394,532	56,911
Accounts payable	1,050,215	1,096,125
Accrued expenses	1,447,975	789,482
Derivative revenue	12,500	0
Total current liabilities	8,905,222	1,942,518
Long-term debt	0	7,290,881
Deferred tax liability	2,500,000	2,500,000
Warrant liability	7,509,630	8,171,518
Derivative liability	1,056,920	2,120,360
Other long-term liabilities	170,403	255,606
Total liabilities	20,142,175	22,280,883
Commitments and contingencies
Preferred stock		0
Preferred stock series B, $0.001 par value; subscription receivable		(210,000)
Fibrocell Science, Inc. shareholders' equity/(deficit):
Common stock, $0.001 par value; 250,000,000 shares authorized 95,278,255 and 20,375,500 shares issued and outstanding, respectively	95,278	20,376
Common stock; $0.001 par value; subscription receivable	(2,038,733)	0
Additional paid-in capital	43,421,317	2,437,893
Accumulated deficit during development stage	(38,275,135)	(17,981,530)
Total Fibrocell Science, Inc. shareholders' equity/(deficit)	3,202,727	(15,523,261)
Noncontrolling interest	491,116	450,373
Total equity/(deficit) and noncontrolling interest	3,693,843	(15,072,888)
Total liabilities, preferred stock, shareholders' equity/(deficit) and noncontrolling interest	23,836,018	8,278,145
Successor | Series A Preferred Stock
Current liabilities:
Preferred stock	0	1,280,150
Successor | Series B Preferred Stock
Current liabilities:
Preferred stock	0
Preferred stock series B, $0.001 par value; subscription receivable	0
Series D Preferred Stock
Current liabilities:
Preferred stock	$ 0	$ 0